Work

Supplementary Tables 1 - 3 from Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 104K, Supplementary Table S1. Vismodegib Dosing Strategy Supplementary Table S2. Commonly Reported Adverse Events According to Grade Supplementary Table S3. Pharmacokinetics of Unbound Vismodegib in Pediatric Patients with Medulloblastoma

DOI: 10.1158/1078-0432.22451898

Authors: Amar Gajjar, Clinton F. Stewart, David W. Ellison, Sue Kaste, Larry E. Kun, Roger J. Packer, Stewart Goldman, Murali Chintagumpala, Dana Wallace, Naoko Takebe, James M. Boyett, Richard J. Gilbertson, Tom Curran

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361883156

Cites:

Cited by:

Related to: 10